Insider Buying: Savara Inc (NASDAQ:SVRA) Director Acquires $20,800.00 in Stock

Savara Inc (NASDAQ:SVRA) Director Joseph S. Mccracken bought 10,000 shares of Savara stock in a transaction on Thursday, May 29th. The stock was purchased at an average price of $2.08 per share, for a total transaction of $20,800.00. Following the completion of the acquisition, the director now owns 260,837 shares in the company, valued at $542,540.96. This represents a 3.99% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Savara Stock Performance

SVRA stock opened at $2.49 on Thursday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The stock has a market capitalization of $430.36 million, a price-to-earnings ratio of -5.79 and a beta of 0.44. Savara Inc has a 1 year low of $1.89 and a 1 year high of $5.11. The stock’s fifty day moving average is $2.89 and its two-hundred day moving average is $2.93.

Savara (NASDAQ:SVRA) last posted its earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.12). On average, research analysts predict that Savara Inc will post -0.45 EPS for the current year.

Institutional Investors Weigh In On Savara

A number of hedge funds have recently added to or reduced their stakes in SVRA. SG Americas Securities LLC lifted its stake in Savara by 14.0% in the fourth quarter. SG Americas Securities LLC now owns 51,589 shares of the company’s stock valued at $158,000 after buying an additional 6,330 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Savara by 14.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock valued at $112,000 after buying an additional 4,732 shares during the last quarter. Rhumbline Advisers lifted its stake in Savara by 6.8% in the fourth quarter. Rhumbline Advisers now owns 141,425 shares of the company’s stock valued at $434,000 after buying an additional 9,041 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Savara by 7.6% during the fourth quarter. Bank of New York Mellon Corp now owns 253,630 shares of the company’s stock valued at $779,000 after purchasing an additional 17,870 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Savara by 5.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 963,821 shares of the company’s stock valued at $2,959,000 after purchasing an additional 52,204 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Wells Fargo & Company cut their price objective on shares of Savara from $8.00 to $7.00 and set an “overweight” rating on the stock in a report on Wednesday, May 28th. HC Wainwright lowered shares of Savara from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $6.00 to $2.00 in a report on Thursday, May 29th. Evercore ISI cut their price objective on shares of Savara from $3.00 to $2.00 and set an “in-line” rating on the stock in a report on Wednesday, May 28th. Finally, Guggenheim reiterated a “buy” rating and set a $8.00 price objective (down from $9.00) on shares of Savara in a report on Wednesday, May 28th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $7.17.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.